Epix' collagen-binding MRI agent shows early promise for potentially large heart attack market
This article was originally published in Clinica
Executive Summary
A collagen-specific MRI contrast agent being developed by Epix Pharmaceuticals has shown early promise for differentiating healthy, viable heart muscle from non-viable heart muscle that has resulted from a heart attack.